126 related articles for article (PubMed ID: 9402329)
1. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
Burk M; Heyll A; Arning M; Volmer M; Fartash K; Schneider W
Leuk Lymphoma; 1997 Oct; 27(3-4):321-7. PubMed ID: 9402329
[TBL] [Abstract][Full Text] [Related]
2. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
Lindner LH; Ostermann H; Hiddemann W; Kiani A; Würfel M; Illmer T; Karsch C; Platzbecker U; Ehninger G; Schleyer E
Int J Hematol; 2008 Nov; 88(4):381-386. PubMed ID: 18836794
[TBL] [Abstract][Full Text] [Related]
3. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
[TBL] [Abstract][Full Text] [Related]
4. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Braess J; Freund M; Hanauske A; Heil G; Kaufmann C; Kern W; Schüssler M; Hiddemann W; Schleyer E
Leukemia; 1998 Oct; 12(10):1618-26. PubMed ID: 9766508
[TBL] [Abstract][Full Text] [Related]
5. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T
Ther Drug Monit; 1996 Aug; 18(4):341-9. PubMed ID: 8857548
[TBL] [Abstract][Full Text] [Related]
6. Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma.
Burk M; Volmer M; Fartash K; Schneider W
Arzneimittelforschung; 1995 May; 45(5):616-9. PubMed ID: 7612064
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
Donnette M; Solas C; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Hau LTT; Costello R; Ouafik L; Lacarelle B; Ciccolini J; Fanciullino R
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121770. PubMed ID: 31454720
[TBL] [Abstract][Full Text] [Related]
8. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
Periclou AP; Avramis VI
Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
[TBL] [Abstract][Full Text] [Related]
9. Excretion of cytosine arabinoside in saliva after its administration at high doses.
Mori T; Yamazaki R; Nakazato T; Aisa Y; Enoki S; Arai M; Ikeda Y; Okamoto S
Anticancer Drugs; 2006 Jun; 17(5):597-8. PubMed ID: 16702818
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
11. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
[TBL] [Abstract][Full Text] [Related]
12. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
Zwierzina H; Suciu S; Loeffler-Ragg J; Neuwirtova R; Fenaux P; Beksac M; Harousseau J; Nuessler V; Cermak J; Solbu G; Willemze R; de Witte T; Amadori S;
Leukemia; 2005 Nov; 19(11):1929-33. PubMed ID: 16151466
[TBL] [Abstract][Full Text] [Related]
13. Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells.
Braess J; Pförtner J; Kern W; Hiddemann W; Schleyer E
Ann Hematol; 1999 Nov; 78(11):514-20. PubMed ID: 10602895
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytarabine (HD araC) in the treatment of leukemias: a review.
Reese ND; Schiller GJ
Curr Hematol Malig Rep; 2013 Jun; 8(2):141-8. PubMed ID: 23666364
[TBL] [Abstract][Full Text] [Related]
16. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
17. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
19. HPLC-MS/MS method for the simultaneous determination of MB07133 and its metabolites, cytarabine and arabinofuranosyluracil, in rat plasma.
Wang D; Xiao Q; Yang W; Qian W; Yang J
J Pharm Biomed Anal; 2016 Feb; 120():228-34. PubMed ID: 26760240
[TBL] [Abstract][Full Text] [Related]
20. Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
Braess J; Wegendt C; Feuring-Buske M; Riggert J; Kern W; Hiddemann W; Schleyer E
Br J Haematol; 1999 May; 105(2):388-93. PubMed ID: 10233409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
